Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases.

about

Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases.

Item

http://www.wikidata.org/entity/Q47140442

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Ruxolitinib combined with vori ...... ype in hematological diseases.

@en

Ruxolitinib combined with vori ...... ype in hematological diseases.

@nl

type

Item

label

Ruxolitinib combined with vori ...... ype in hematological diseases.

@en

Ruxolitinib combined with vori ...... ype in hematological diseases.

@nl

prefLabel

Ruxolitinib combined with vori ...... ype in hematological diseases.

@en

Ruxolitinib combined with vori ...... ype in hematological diseases.

@nl

P1476

Ruxolitinib combined with vori ...... ype in hematological diseases.

@en

P2093

Maria Cosenza

http://www.w3.org/2001/XMLSchema#string

Monica Civallero

http://www.w3.org/2001/XMLSchema#string

Samantha Pozzi

http://www.w3.org/2001/XMLSchema#string

Stefano Sacchi

http://www.w3.org/2001/XMLSchema#string

P2860

Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis

Modulation of autoimmune diseases by interleukin (IL)-17 producing regulatory T helper (Th17) cells

Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells

Different Mechanisms of Regulation of the Warburg Effect in Lymphoblastoid and Burkitt Lymphoma Cells

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Mitochondria and apoptosis

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

On respiratory impairment in cancer cells

Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.

Teaching the basics of cancer metabolism: Developing antitumor strategies by exploiting the differences between normal and cancer cell metabolism

P304

103797-103814

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.21951

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29262601

http://www.w3.org/2001/XMLSchema#string

P932

5732767

http://www.w3.org/2001/XMLSchema#string